Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Nonreplicating Virus Kills Leukemia in Mouse and Culture Models

By BiotechDaily International staff writers
Posted on 27 Aug 2013
Image: Electron micrograph depicts the rhabdovirus responsible for vesicular stomatitis (VS) in horses, cattle, and pigs. An inactivated rhabdovirus was used in recent studies to destroy leukemia cells (Photo couryesy of the [US] Centers for Disease Control (CDC)).
Image: Electron micrograph depicts the rhabdovirus responsible for vesicular stomatitis (VS) in horses, cattle, and pigs. An inactivated rhabdovirus was used in recent studies to destroy leukemia cells (Photo couryesy of the [US] Centers for Disease Control (CDC)).
A biopharmaceutical drug comprising nonreplicating virus particles killed leukemia cells in a mouse leukemia model and in cultures of cells taken from patients with multiple drug resistant forms of the disease.

Investigators at the University of Ottawa (Canada) speculated that high doses on a nonreplicating virus would be able to kill blood cancer cells without the dangers inherent in the use of fully competent live viruses. Toward this end they developed a method based on attenuation with UV light to produce unique high-titer bioactive yet nonreplicating rhabdovirus-derived particles (NRRPs).

This novel NRRP bio-drug was shown in a paper published in the July 12, 2013, online edition of Blood Cancer Journal to possess direct cytolytic and immunomodulatory activity against acute leukemia. In a mouse model of leukemia treated with the NRRPs 80% of the mice had markedly prolonged survival and 60% were eventually cured of the disease, while all of the untreated mice died of leukemia within 20 days.

In laboratory cultures, NRRP resistance in normal cells was mediated by intact antiviral defenses including interferon (IFN). In contrast, NRRPs administered cell cultures derived from clinical samples obtained from patients with high-burden multidrug-resistant acute myeloid leukemia killed the cancer cells.

"Our research indicated that a replicating virus might not be the safest or most effective approach for treating leukemia, so we decided to investigate whether we could make virus-derived particles that no longer replicate but still kill cancer," said senior author Dr. David Conrad, a doctor candidate in cellular and molecular medicine at the University of Ottawa. "We were delighted to see that this novel therapy was very safe at high doses, and worked extremely well in our laboratory leukemia models. We hope to test this in patients in the near future."

"Leukemia is a devastating disease that can be very difficult to treat, and new therapies are urgently needed," said Dr. Conrad. "While we are still at the early stages of this research, I think this therapy holds a lot of promise because it appears to have a potent, long-lasting effect on leukemia without the debilitating side effects of many cancer therapies used in the clinic right now. We will likely see even better results once we optimize the dose in our preparations to advance this research into human clinical trials."

Related Links:
University of Ottawa


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.